Indefinite Delivery Contract 75D30123D16461
Award Date
8/15/23
Last Date to Order
8/14/28
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
R799 - Support- Management: Other
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Service Contract Act
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded a single award indefinite delivery contract to Pfizer Inc. for vaccine storage and rotation services. The contract has a potential value of $3 million with a firm fixed price delivery order issued for $2.3 million. Pfizer will provide storage and rotation of vaccines from August 1, 2022 through July 31, 2027 in New York, New York. The contract aims to procure vaccine storage and rotation services from Pfizer to support the CDC's vaccine...
The Centers for Disease Control and Prevention awarded a single-award, indefinite delivery contract to Sanofi Pasteur Inc. with a potential value of $13 million to provide vaccine storage and rotation services from December 2021 through November 2026. Under the initial firm fixed price delivery order valued at $1.8 million, Sanofi Pasteur will store and manage approximately 6.7 million doses of various pediatric vaccines at its Swiftwater, Pennsylvania facility in support of CDC programs. The...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
The federal contract IDV awarded to Glaxosmithkline, LLC is a $83,834,950 Indefinite Delivery Contract to provide a range of adult vaccines to the Centers for Disease Control and Prevention (CDC) for a period of performance through June 30, 2019. The single-award contract was issued without any set-aside designation. The contract aims to procure various pharmaceutical products and immunization services to support public health initiatives, including influenza vaccines, hepatitis vaccines,...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Merck Sharp & Dohme Corp., a subsidiary of Schering Plough Corporation, to provide vaccine-related services. The single-award contract has a ceiling value of $56,988,922.50 and a period of performance through February 28, 2011. The contract was not set aside and aims to procure vaccine storage and rotation services. This delivery order contract is one of...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) has awarded a 5-year, $154.3 million indefinite delivery, indefinite quantity (IDIQ) contract to Glaxosmithkline, LLC for the provision of various adult vaccines. The contract period of performance is from July 1, 2024 to June 30, 2025, with vaccines ordered via the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process. The required vaccine types include...